Explore
Validate
LearnPA5-35148
antibody from Invitrogen Antibodies
Targeting: CYP2D6
CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-35148 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CYP2D6 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with rat based on sequence homology.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 0.45 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references β-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP⁺ Toxicity in Human Neuroblastoma SH-SY5Y Cells.
Fernandez-Abascal J, Ripullone M, Valeri A, Leone C, Valoti M
International journal of molecular sciences 2018 Oct 28;19(11)
International journal of molecular sciences 2018 Oct 28;19(11)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Cytochrome P450 2D6 in MDA-MB453 cell lysate (35 µg/lane) using a Cytochrome P450 2D6 polyclonal antibody (Product # PA5-35148).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Cytochrome P450 2D6 in formalin-fixed, paraffin-embedded human liver tissue using a Cytochrome P450 2D6 polyclonal antibody (Product # PA5-35148) followed by peroxidase conjugation of the secondary antibody and DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Effect of beta-NF and EtOH treatment on cytochrome P450 (CYP) isoforms' expression in undifferentiated SH-SY5Y cells. ( a - d ) The graphs show the relative protein levels quantification by Western blot for the CYP2D6 ( a ), 2E1 ( b ), 1A1 ( c ), and 3A4 ( d ) isoforms after treating cells with the inducers for 48 h (see Section 4 ). Data was acquired by measuring the fluorescent intensity per pixel on each band. The relative amount of protein normalised with beta-actin as a housekeeping protein for each condition was plotted as fold-increase and compared to the control, which was given a value of 1. Columns represent the mean +- SEM of at least three different experiments. Statistical significance was analyzed by one-way ANOVA followed by a Tukey post-test (* p < 0.05; ** p < 0.01). ( e ) Top panel shows a representative blot of beta-actin housekeeping protein detected with secondary antibody Cy3 (green) in control (2nd lane), beta-NF (3rd lane) and EtOH (4th lane) treatments. ( e ) Bottom panel shows representative blots of each isoform detected with secondary antibody Cy5 (red) in the mentioned conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Effect of beta-NF and EtOH treatment on cytochrome P450 (CYP) isoforms' expression in undifferentiated SH-SY5Y cells. ( a - d ) The graphs show the relative protein levels quantification by Western blot for the CYP2D6 ( a ), 2E1 ( b ), 1A1 ( c ), and 3A4 ( d ) isoforms after treating cells with the inducers for 48 h (see Section 4 ). Data was acquired by measuring the fluorescent intensity per pixel on each band. The relative amount of protein normalised with beta-actin as a housekeeping protein for each condition was plotted as fold-increase and compared to the control, which was given a value of 1. Columns represent the mean +- SEM of at least three different experiments. Statistical significance was analyzed by one-way ANOVA followed by a Tukey post-test (* p < 0.05; ** p < 0.01). ( e ) Top panel shows a representative blot of beta-actin housekeeping protein detected with secondary antibody Cy3 (green) in control (2nd lane), beta-NF (3rd lane) and EtOH (4th lane) treatments. ( e ) Bottom panel shows representative blots of each isoform detected with secondary antibody Cy5 (red) in the mentioned conditions.
